

Exhibit G

EXHIBIT G**(Abbott's proposed sample of documents for *in camera* review)****CMS Amended Privilege Log**

Document Number	Date	Type	Description	Author	Distribution	Privilege Designation
HHC901-0093-0133 (Released 0131-33)		Memo with Attachments	Request for a Modification to Contract #500-96-0026, Task order #17 re: Prices Established by the Private and Public Sectors for Drugs also Covered Under Medicare Part B	Stoogenke, Marvin M., HCFA Project Officer, Division of Supplier Claims Processing, Center of Health Plans and Providers	Director, HCFA, Div. of Research Contracts and Grants, Acquisition and Grants Group	Deliberative Process
HHC901-0176-0184		Contract Document	Proposed contract to Develop Electronic Drug Pricing Containing Reimbursement Allowances for Drugs Covered Under the Medicare Program by developing an AWP for covered drugs	Broseker, Joseph, HHS Dep. Director in CCHP	Pritchett, Jacqueline Stoogenke, Marvin	Deliberative Process
HHC901-0767		List	Wholesaler Contact Information and Calculations. Handwritten notes regarding Albuterol. Other notes calculating the percentage of spread.			Deliberative Process
HHC901-0788-0789		Memo-Options Memo	Outlining current policy and options re: Dealing with problems and issues arising from use of DOJ AWP data.		Niemann, R	Deliberative Process
HHC901-1018-1028	02/3/1999	Fax with Attachments	First Data Bank Statement Proposal, Government Draft Response and Comments re FDB Price Reports and Threatened Litigation	Stephens, Reed, Department of Justice	Neimann, Bob Riordan, Mary, HHS/OIG	Deliberative Process
HHC902-0005-0016	12/6/1995	Draft proposal	Discussion of an alternative reimbursement mechanism for the Medicare Program's payment for drugs.		(AWP)	Deliberative Process
HHC902-0035-0052	04/29/1996	Draft NPRM	Draft NPRM (BPD852PB.B, pp. B12-B29) on drug and biological pricing policy. Discusses alternative reimbursement mechanisms and the pros and cons of such policies. (See also HHC902- 00010004, HHC902-00190034, HHC902-00810085)			Deliberative Process
HHC902-0053-0055	04/26/1996	Draft NPRM	Draft NPRM (BPD852PC.C, pp. C9-C11) on drug and biological pricing policy. Discusses potential affects of alternative reimbursement mechanisms.			Deliberative Process

HHC902-0080 (Portions redacted)	04/22/1998	Memo w/ handwritten notes	Memo regarding a story on ABC Evening News regarding the quality of compounded drugs dispensed and payment differences for prescription drugs between Medicare beneficiaries and other health care consumers. Contains Mr. Price's suggestion of how to respond to the news story.	Price, William	Peacock, C. Johnson, R.; Proctor, J.; Ruiz, L; Delillo: Joel K; Walt: Bill L: Bob N	Deliberative Process
HHC902-0109-0111	6/30/1993	Draft Memo	Instructions regarding how to determine the acquisition cost of drugs pursuant to 42 CFR 405.517. (See also HHC902-01290131)		All ARAs For Medicare	Deliberative Process
HHC902-0187-0201	2001-2002	List with Attachments	Discussion of numerous alternative reimbursement mechanisms for Medicare-covered drugs. Includes handwritten notes listing and describing many of the possible alternative reimbursement mechanisms (i.e., brainstorming material.)	Greenburg, Alan		Deliberative Process
HHC902-0214-0244	04/1999 - 06/1999	Memo with Attachments	Discussion of the issue regarding alternative reimbursement mechanisms and the use of DOJ data regarding one such alternative. Presents an impact analysis of changes in reimbursement and its potential effect on the delivery of care. Includes different documents, including a memo, handwritten notes and charts. (See also HHC902-02510258)	Hash, Michael Deputy Administrator	Thurm, Kevin Deputy Secretary ES; COS	Deliberative Process
HHC902-0251-0258	04/1999 - 06/1999	Memo	Discussion of the issue regarding alternative reimbursement mechanisms and the use of DOJ data regarding one such alternative. Presents an impact analysis of changes in reimbursement and its potential effect on the delivery of care. (See also HHC902-02140244)	Hash, Michael Deputy Administrator	Thurm, Kevin Deputy Secretary ES; COS	Deliberative Process
HHC902-0271-0310	1997-1998	Draft Memoranda, Email, Handwritten Notes	Series of drafts, notes and emails discussing the pros and cons of an alternative reimbursement mechanism.	Niemann, Robert; Buto, Kathleen; Schumaker, Bernadette	Schumaker, Bernadette; Wynn, B.	Deliberative Process
HHC902-0315	05/XX/1997	Stickie/Note	Handwritten note regarding drafting of future legislation or regulations concerning payment for drugs.	Bart	Niemann, Bob	Deliberative Process
HHC902-0355-0360	10/20/1998	Draft Final Rule w/ Handwritten Notes	Draft of preamble to final rule. Includes discussion of NPRM previously issued implementing the BBA. Includes responses to the comments received			Deliberative Process

			during the comment period. (See HHC902-03610368, HHC902-03760381)			
HHC902-0545-0547	02/19/1993	Memo	Response to memo regarding Medicaid Bureau's response to the Philadelphia Regional Office concerning Pennsylvania's proposal to contract with one pharmaceutical company to provide prescriptions by mail. Discusses The Medicaid Bureau's response and the applicable law the Regional Office must consider when evaluating this policy.	Abato, Rozann, HHS/HCFA Acting Director Medicaid Bureau	Division of Medicaid Region II, New York Associate Regional Administrator Regional Administrators: Boston, New York, Philadelphia, Atlanta, Chicago, Dallas, Kansas City, Denver, San Francisco, Seattle	Deliberative Process
HHC902-0646-0651 (Released 649)	06/28/1990	Memorandum with Attachments	Memorandum in response to request for clarification of HCFA policy relating to Estimated Acquisition Cost (EAC) and rebates from manufacturers. Memo clarifies the language in the regulation in light of the requesting party's initial understanding.	Abato, Rozann, DHHS/ Medicaid Bureau Acting Director	Associate Regional Administrator, Region II	Deliberative Process
HHC902-0795-0800	mid-1997	Draft Memo w/ Attachments	Provides background on and transmits HHS report to Congress on the average wholesale price of drugs as mandated by Section 4556 of the Balanced Budget Act of 1997. Attachments include draft letters to various members of Congress introducing the report.	Min DeParle, Nancy-Ann The Administrator, HCFA	Shalala, Donna Secretary, HHS	Deliberative Process
HHC902-0875-0877	02/1/1993	Memorandum	Request for additional information on various unresolved issues following a teleconference with state pharmacists regarding the federal upper limit list. Attachment is a list of 18 drugs and the corresponding federal upper limit, AWP unit cost, NE unit cost, unit rebate and net unit cost for each.	Abato, Rozann, HCFA Acting Director, Medicaid Bureau	Associate Regional Administrator, Division of Medicaid, Kansas City Regional Administrator Kansas City; Rodler. Pete; Reed; Abato, Rozann	Deliberative Process
HHC902-1078-1089	09/28/1987	Speech	Draft of speech titled "The Complicated History of Medicaid Regulations on Drug Reimbursement." Discussion of regulations from 1975 to 1987. Discusses Dr. Helms' assessment of the new final rule.	Helms, Robert B. Assistant Secretary For Planning and Evaluation		Deliberative Process
HHC903-0046-0049	07/13/1990	Draft Report	Brief Overview of the Federal Medicaid Prescription Drug Program; states' payment methodologies as applied to multiple source drugs and for all other drugs	Rodler, Pete Medicaid Bureau		Deliberative Process
HHC903-0103-	08/11/1988	Memo	Drug Reimbursement	Rodler, Pete		Deliberative

0110			Reform Regulations as applied to Maximum Allowable Cost (MAC) program, Pharmacists' Incentive Program (PhIP), and Competitive Incentive Program (CIP); state plan process			Process
HHC903-0458-0461	08/14/1997	Memo	Significant Activities for the Week Ending August 8, 1997: detailing items of interest, significant activities for the administrator, meetings with particular entities and contact info. Includes discussion of TAP litigation.	Fried, Bruce Merlin Director, Center For Health Plans and Providers	The Administrator	Deliberative Process
HHC903-0678-0679	09/16/1986	Memo	Medicare Coverage of Drug Delivery Systems- Assessment of what drug/treatment/device combinations should be focused upon	Buto, K Acting Deputy Director, Bureau of Eligibility, Reimbursement and Coverage	Director, Office of Health Technology Assessment	Deliberative Process
HHC903-0894-0904	03/30/1994	Email and attachments	discussing how HCFA should interpret and use pricing data to determine AWP	Mirabal, Joe Reimbursement Specialist, HCFA, New York City	Weintraub, Stanley HCFACOM	Deliberative Process
HHC903-0966-0974	2/1/1994	Draft	Discussing different alternatives to help carriers determine Acquisition Cost of Drugs		All ARAs For Medicare	Deliberative Process
HHC904-0145-0154		Letters and attachments	Draft response to letter re: Oregon's state plan amendment to redefine the state's EAC for drugs from AWP minus 14 percent to AWP minus 15 percent.	Smith, Dennis G. Director	Coster, JohnM., Ph.D., R., PH. Vice President, Policy and Programs, National Association of Chain Drug Stores Garza, Maria, Seattle Regional Office	Deliberative Process
HHC904-0182-0191	11/7/2002	Draft report and handwritten notes	Discussing Options for Obtaining Better Drug Pricing Data for Both Medicaid and Medicare to obtain AWP figures			Deliberative Process
HHC904-0603-0606		Draft memo	Subject;Determination of Medicaid Prescription Drug Estimated Acquisition Cost (EAC); Discussing generally, state plan amendment requests that propose to change reimbursement methodology and how to analyze these state plans.	Director, Family and Children's Health Program Group	Director, Center for Medicaid and State Operations	Deliberative Process
HHC905-1083-1599	Report		Appendix II Top 60 Drug Data, Final Report on the "Prices Established by the Private and Public Sectors for Drugs Also Covered Under Medicare Part B"	Jing Xing Technologies, Inc		Deliberative Process
HHC906-0166-	06/13/1991	Memo and	Request for Guidance on	Buto, K. A.	Chief, Carrier	Deliberative

0171 (Redacted portions on 170)		attachment	Limiting the Charge for Drugs/ Biologicals provided by Physicians (Your memo dated 11/8/90) [copy of HHC903-08650868]	Director, Bureau of Policy Development	Operations Branch Associate Regional Administrator, Region V, Chicago	Process
HHC906-0558-0559		Letter (draft)	Draft letter discussing Colorado's State Plan Amendment (SPA) 02-011, which would modify the estimated acquisition cost for prescription drugs, increasing the discount to AWP less 14% for brand name drugs and AWP less 45% for generics	Reed, L. Co-Director, Pharmacy Team, CMS	Chaumont, Vivianne Director, Office of Medical Assistance, Dept. of Health Care Policy & Financing Ericson, Spencer, Acting Associate Regional Administrator	Deliberative Process
HHC906-0585-0586		Draft	Draft letter discussing Colorado's State Plan Amendment (SPA) 02-011, which would modify the estimated acquisition cost for prescription drugs, increasing the discount to AWP less 14% for brand name drugs and AWP less 45% for generics.	Reed, Larry, Department of Health & Human Services Co-Director, Pharmacy Team	Allen, Richard, Office of Medical Assistance Director Ericson, Spencer, Denver Regional Office	Deliberative Process
HHC907-0852-0860	04/14/1998	Notes handwritten	RE: Inherent Reasonableness teleconference; Bulletins-cost factors; draft of strategy for implementing IR standard.	Schoen, T.		Deliberative Process

OIG Office of Evaluations and Inspections Privilege Log

Document Number	Date	Type	Description	Author	Distribution	Privilege Designation
HHD900-1065 - HHD900-1067	11/16/2000	Notes	Entrance Conference Notes on "The Effect of More Accurate AWP's on Medicaid Drug Payments"	OEI Staff		Deliberative Process
HHD900-1122	5/30/2000	Notes	Exit Conference Notes on OEI Report 03-01-00010 (The Effect of More Accurate AWP's on Medicaid Drug Payments)	OEI Staff		Deliberative Process
HHD900-1513	6/5/1997	Email	Email without Subject w/ proposed language of regulation	Alec Vachon, Staffer on Senate Finance Committee	George Grob, Deputy Inspector General for Evaluation and Inspection; Robert Vito, Regional Inspector General for Evaluation and Inspection	Deliberative Process

HHD900-1705 - HHD900-1715	5/3/1995	Notes	Notes Summarizing Conference Call	OEI Staff		Deliberative Process
HHD900-1716 - HHD900-1722		Notes	Handwritten Notes and Figure Summaries	OEI Staff		Deliberative Process
HHD900-1818	7/30/1996	Memo	Memo re: Revision to Section 3060.D of the Medicare Carriers Manual Concerning Reassignment- ACTION	Thomas Ault, Director, Bureau of Policy Development- HCFA	All Regional Administrators	Deliberative Process
HHD900-1909 - HHD900-1911		Notes	Summary Notes of Entrance Conference	Robert Katz, Program Analyst	File	Deliberative Process
HHD900-1976 - HHD900-1978		Notes	Summary of Exit Conference	Robert Katz, Program Analyst	File	Deliberative Process
HHD900-2121 - HHD900-2128		Notes	Notes on drug pricing re: 1996 HCFA proposal for Medicare Program Payment for Drugs	OEI Staff		Deliberative Process
HHD900-2237 - HHD900-2238		Memo	Memo re: Summary of Exit Conference for OEI report 03-94- 00390 (Medicare Payments for Nebulizer Drugs)	Robert Katz, Program Analyst	File	Deliberative Process
HHD900-2274	5/27/1998	Notes	Notes from Exit Conference for OEI report 03-97-00293 (Comparing Drug Reimbursement: Medicare and Department of Veterans Affairs)	OEI Staff		Deliberative Process
HHD900-2536	4/18/2000	Notes	Entrance Conference Notes for OEI reports 03-00-00310 (Medicare Reimbursement of Prescription Drugs) and 03-00-00311 (Medicare Reimbursement of Albuterol)	OEI Staff		Deliberative Process

OIG Office of Audit Services Privilege Log

Document Number	Date	Type	Description	Author	Distribution	Privilege Designation
HHD902-0496- HHD902-0497	8/1/1996	Correspondence	Comments on Draft Report - Pharmacy Acquisition Costs of the Delaware Medicaid Program	Carmen Nazario, Secretary, Delaware Health & Social Services	June Gibbs- Brown, IG; cc's: Elaine Archangelo, Phil Soule, Sr., & Cindy Denemark	Deliberative Process
HHD902-0583- HHD902-0594	9/0/1994	Letter	Draft Letter relating to A-06-95-00066			Deliberative Process
HHD902-0707- HHD902-0717	09/0/1994	Letter	Draft letter re: Pharmacy Acquisition Costs for Drugs Reimbursed Under the			Deliberative Process

			Prescription Drug Program of the District of Columbia			
--	--	--	---	--	--	--